| P2093 | author name string | Masaki Saito | |
| | Nobuhiro Aizawa | |
| | Shuhei Nishiguchi | |
| | Yoshihiko Yano | |
| | Hirayuki Enomoto | |
| | Tomoyuki Takashima | |
| | Yoshinori Iwata | |
| | Masahiko Sugano | |
| | Hiroaki Okushin | |
| | Hideji Nakamura | |
| | Soo Ryang Kim | |
| | Susumu Imoto | |
| | Toshiaki Ninomiya | |
| | Michiko Shindo | |
| | Hiroyasu Imanishi | |
| | Yasushi Seo | |
| | Akira Muramatsu | |
| | Hiroshi Kasugai | |
| | Hisato Jomura | |
| | Soji Shimomura | |
| | Hiroko Iijma | |
| | Teruji Ooka | |
| P2860 | cites work | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 |
| | Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 |
| | Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups | Q29614459 |
| | Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 |
| | Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 |
| | The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 |
| | Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | Q29620702 |
| | Antiviral therapy for chronic hepatitis C: past, present, and future | Q36406543 |
| | Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response | Q42670765 |
| | Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death | Q42983596 |
| | Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus | Q42987918 |
| | Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group | Q42987938 |
| | Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 |
| | Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response | Q42992693 |
| | Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. | Q42993815 |
| | Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response | Q42994528 |
| | Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin | Q42999474 |
| | Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy | Q42999651 |
| | Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. | Q43001787 |
| | Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy | Q43031896 |
| | Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan | Q43039581 |
| | Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha | Q43040253 |
| | Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. | Q43046858 |
| | Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial | Q43048287 |
| | Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy | Q43049563 |
| | Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis | Q45004226 |
| | Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response | Q45174259 |
| | Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis | Q45414516 |
| | Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. | Q50569718 |
| | Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. | Q50571579 |
| | Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. | Q50578652 |
| | Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. | Q50650208 |
| | Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. | Q52909973 |
| | Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. | Q53460454 |
| P433 | issue | 6 | |
| P921 | main subject | ribavirin | Q421862 |
| | Hepatitis C virus | Q708693 |
| | pegylated interferon | Q7160835 |
| P304 | page(s) | 597-607 | |
| P577 | publication date | 2013-05-31 | |
| P1433 | published in | Hepatology Research | Q15752035 |
| P1476 | title | Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment | |
| P478 | volume | 44 | |